Vinorelbine treatment of recurrent salivary gland carcinomas.

Abstract

Twenty patients (13 males, 7 females, median age 61 years, range 27-74) with recurrent adenocarcinoma-like tumors of major (10 patients) and minor (10 patients) salivary gland origin (13 adenoid cystic carcinoma, 5 adenocarcinoma, 1 malignant mixed tumor, 1 undifferentiated carcinoma) were treated with vinorelbine at the dose of 30 mg/m2 i.v. weekly. Sixteen patients had been previously treated with surgery + radiation, 3 with surgery + radiotherapy + Novantrone and 1 with radiotherapy alone. Nine patients had local recurrence, 2 local relapse + metastasis and 9 metastasis alone. Site of metastases are: lung (7), bone (1), lung + bone (2), lung + bone + lymph-node + skin (1). Overall 174 courses were given (median 9, range 6-19). Responses were: PR in 4 patients (20%) with a median duration of 6 months (3-9), 9 NC (45%) with a median duration of 3.5 months and 7 PD (35%). The median survival time was 10 months for PR/NC patients, 4 months for non-responders. Median overall survival was 7 months. Vinorelbine has a moderate activity in these very advanced cases.

• Authors: M Airoldi, C Bumma, O Bertetto, P Gabriele, G Succo, F Pedani
• Journal: Bulletin du cancer (Bull Cancer) Vol. 85 Issue 10 Pg. 892-4 (Oct 1998) ISSN: 0007-4551 [Print] France
• PMID: 9835866 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Phytogenic
• Vinblastine
• Vinorelbine

Topics

• Adenocarcinoma (drug therapy)
• Adenoma, Pleomorphic (drug therapy)
• Adult
• Aged
• Antineoplastic Agents, Phytogenic (therapeutic use)
• Carcinoma (drug therapy)
• Carcinoma, Adenoid Cystic (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Salivary Gland Neoplasms (drug therapy)
• Vinblastine (analogs & derivatives, therapeutic use)
• Vinorelbine